Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3]

Completed

Conditions: Metastatic Nonsmall Cell Lung Cancer

Interventions: Drug: Pemetrexed
Drug: Pembrolizumab
Drug: Carboplatin
Drug: Cisplatin

First Posted Date: 2024-09-23

Last Posted Date: 2024-09-23

Lead Sponsor: Aetion, Inc.

Target Recruit Count: 851

Registration Number: NCT06607393

Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer

Phase 2

Not yet recruiting

Conditions: Breast Cancer
Triple Negative Breast Cancer

Interventions: Drug: Pembrolizumab
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2024-09-20

Last Posted Date: 2024-10-28

Lead Sponsor: MedSIR

Target Recruit Count: 30

Registration Number: NCT06604858

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors

Phase 1

Not yet recruiting

Conditions: Non-Small Cell Lung Cancer
Advanced Solid Tumors

Interventions: Drug: HS-10370
Drug: Adebrelimab
Drug: Cisplatin
Drug: Pemetrexed
Drug: Carboplatin

First Posted Date: 2024-09-13

Last Posted Date: 2024-09-13

Lead Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

Target Recruit Count: 350

Registration Number: NCT06594874

Locations: 🇨🇳
Union Hospital Tong Ji Medical College, HuaZhong University of Science and Technology, Wuhan, Hubei, China

CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4]

Completed

Conditions: Metastatic Non Small Cell Lung Cancer

Interventions: Drug: Pembrolizumab
Drug: Pemetrexed
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2024-09-05

Last Posted Date: 2024-09-05

Lead Sponsor: Aetion, Inc.

Target Recruit Count: 304

Registration Number: NCT06585189

A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features

Phase 3

Recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Datopotamab Deruxtecan
Drug: Carboplatin
Drug: Rilvegostomig
Drug: Cisplatin
Drug: Etoposide
Drug: Pemetrexed
Drug: Vinorelbine
Drug: UFT

First Posted Date: 2024-08-21

Last Posted Date: 2024-12-16

Lead Sponsor: AstraZeneca

Target Recruit Count: 660

Registration Number: NCT06564844

Locations: 🇻🇳
Research Site, Vinh, Vietnam

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 1-49%

Phase 3

Recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Pembrolizumab
Drug: Nivolumab
Drug: Relatlimab
Drug: Carboplatin
Drug: Pemetrexed
Drug: Cisplatin

First Posted Date: 2024-08-20

Last Posted Date: 2024-12-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 800

Registration Number: NCT06561386

Locations: 🇺🇸
Saint Elizabeth Medical Center Edgewood, Edgewood, Kentucky, United States
🇺🇸
Local Institution - 0369, Canton, Ohio, United States
🇧🇷
Local Institution - 0382, Fortaleza, Ceará, Brazil

and more 214 locations